Cas No. 137862-53-4 (valsartan): A Comprehensive Overview

By Author: verdant Pharma
Total Articles: 26
Comment this article

In modern medicine, the management of cardiovascular diseases has become increasingly advanced, with several classes of drugs designed to control blood pressure and improve heart health. One such important compound is Valsartan, identified by CAS No. 137862-53-4. This compound belongs to a class of medications known as angiotensin II receptor blockers (ARBs) and plays a crucial role in treating hypertension and related conditions.

Chemical Identity and Properties
Valsartan is a synthetic, non-peptide compound with the molecular formula C₂₄H₂₉N₅O₃ and a molecular weight of approximately 435.5 g/mol. It appears as a white to slightly off-white powder and exhibits moderate solubility in organic solvents such as DMSO. Its melting point typically falls in the range of 116–117°C, indicating good thermal stability for pharmaceutical applications.
Structurally, valsartan contains a biphenyl-tetrazole moiety, which is characteristic of many ARBs. This structure is critical for its biological activity, allowing it to selectively interact with angiotensin II receptors in the body.
Pharmacological ...
... Classification
Valsartan belongs to the angiotensin II receptor blocker (ARB) class. These drugs are widely used in cardiovascular therapy due to their ability to regulate blood pressure without some of the side effects associated with older drug classes.
Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs such as valsartan do not interfere with bradykinin metabolism. This distinction is important because it reduces the likelihood of side effects like persistent cough, which are commonly seen with ACE inhibitors.
Mechanism of Action
The therapeutic action of valsartan is based on its ability to selectively block the angiotensin II type 1 (AT1) receptor. Angiotensin II is a hormone that causes blood vessels to constrict and stimulates the release of aldosterone, leading to increased blood pressure.
By blocking AT1 receptors, valsartan:
Prevents vasoconstriction (narrowing of blood vessels)

Reduces aldosterone secretion

Promotes vasodilation (widening of blood vessels)

Helps maintain electrolyte and fluid balance

This selective inhibition leads to a significant reduction in blood pressure without affecting heart rate or causing rebound hypertension upon discontinuation.
Additionally, valsartan does not inhibit ACE or renin activity, making it a targeted and efficient antihypertensive agent.
Therapeutic Uses
Valsartan is widely used in the treatment of various cardiovascular conditions, including:
1. Hypertension
It is commonly prescribed for managing mild to moderate high blood pressure. By lowering vascular resistance, valsartan helps reduce strain on the heart and arteries.
2. Heart Failure
Valsartan improves cardiac function in patients with heart failure by reducing afterload and improving blood circulation.
3. Post-Myocardial Infarction Care
Patients recovering from a heart attack benefit from valsartan, as it lowers the risk of cardiovascular mortality and prevents further complications.
4. Renal Protection
In patients with diabetes or kidney-related hypertension, valsartan can reduce proteinuria and protect kidney function, making it valuable in long-term disease management.
Pharmacokinetics
After oral administration, valsartan begins to show its antihypertensive effects within 2 hours, with peak activity occurring between 4 to 6 hours. The effects can last for up to 24 hours, allowing for once-daily dosing in many cases.
Maximum therapeutic benefit is typically achieved after 2 to 4 weeks of continuous use, making adherence to prescribed therapy essential for optimal outcomes.
Advantages Over Other Therapies
Valsartan offers several advantages compared to other antihypertensive drugs:
Lower incidence of cough compared to ACE inhibitors

No significant effect on heart rate

Minimal impact on metabolic parameters such as cholesterol, glucose, and triglycerides

Renal protective effects, especially in diabetic patients

These benefits contribute to its widespread use as a first-line treatment option for hypertension and cardiovascular diseases.
Safety and Considerations
While valsartan is generally well tolerated, certain precautions should be considered:
It may cause hypotension (low blood pressure), especially in dehydrated individuals

There is a risk of hyperkalemia (elevated potassium levels), particularly when combined with other medications affecting potassium balance

Patients with renal impairment should be monitored closely

Drug interactions with NSAIDs and other antihypertensive agents may affect efficacy or safety

As with any pharmaceutical compound, appropriate medical supervision is necessary to ensure safe and effective use.
Industrial and Research Relevance
Beyond its clinical use, valsartan (CAS No. 137862-53-4) is also significant in pharmaceutical research and development. It serves as a model compound in studies involving:
Cardiovascular drug design

Receptor-targeted therapies

Structure-activity relationship (SAR) analysis

Its well-characterized mechanism and efficacy make it a valuable reference in medicinal chemistry.
Conclusion
Valsartan, identified by CAS No. 137862-53-4, stands as a cornerstone in the treatment of hypertension and cardiovascular disorders. Its selective mechanism of action, favorable safety profile, and proven clinical efficacy have made it a widely utilized therapeutic agent.
By effectively blocking angiotensin II receptors, valsartan helps regulate blood pressure, protect vital organs, and improve overall cardiovascular health. As research continues to evolve, this compound remains an important example of how targeted pharmacology can lead to better patient outcomes and improved quality of life.
Other recommended Link: Irbesartan intermediate manufacturers